Rifaximin for Preventing Acute Graft Versus Host Disease (AGVHD)

计划入组 20 人 · 首次发布于 2009 年 8 月 27 日

Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease

计划入组 259 人 · 首次发布于 2012 年 1 月 30 日

Analysis of Biomarkers for Acute Graft-versus-Host Disease (GVHD)

首次发布于 2012 年 4 月 3 日

Graft-versus-host disease therapeutics (Mallinckrodt)

Abatacept(Orencia)

Rx

Graft-versus-host disease therapy(Applied StemCell, Inc.)

Theriva Biologics

United States

Vascular Graft Solutions Ltd.

Israel

Rare Disease Research, LLC

Cynata Therapeutics Completes Phase 2 Trial Evaluation for Stem Cell Therapy Targeting Acute Graft-Versus-Host Disease

Cynata Therapeutics Completes Enrollment in Phase 2 Trial of CYP-001 for Acute Graft-Versus-Host Disease

ReAlta Reports Promising Phase 2 Results for Pegtarazimod in Steroid-Refractory Acute Graft-Versus-Host Disease